急性腦梗死患者發(fā)生阿司匹林抵抗的危險因素

張仕娟，宋玉寧，李乃坤，孫錫波，李炳選

(濰坊醫(yī)學院附屬益都中心醫(yī)院，山東青州 262500)

?

急性腦梗死患者發(fā)生阿司匹林抵抗的危險因素

張仕娟，宋玉寧，李乃坤，孫錫波，李炳選

(濰坊醫(yī)學院附屬益都中心醫(yī)院，山東青州 262500)

目的探討急性腦梗死患者發(fā)生阿司匹林抵抗(AR)的危險因素。方法162例急性腦梗死患者于入院當日開始口服阿司匹林腸溶片100 mg/d，服用阿司匹林10 d后，根據血小板聚集實驗結果將患者分為阿司匹林抵抗(AR)者(AR組，49例)和非AR者(非AR組，113例)，收集患者一般臨床資料，采用實時熒光定量PCR檢測血小板中微小RNA-19a(miR-19a)，利用多因素Logistic回歸分析法分析影響AR發(fā)生的影響因素，利用受試者工作特征曲線(ROC曲線)評估血小板miR-19a表達量預測AR的價值。結果AR組血小板miR-19a表達量為0.78±0.09、2型糖尿病26例(53.1%)，非AR組血小板miR-19a表達量為0.59±0.11、2型糖尿病34例(30.1%)，兩組比較，P均<0.05。多因素Logistic回歸分析顯示，血小板miR-19a表達量升高是影響急性腦梗死患者發(fā)生AR的獨立危險因素(OR=4.82，95%CI：1.374～15.835)。ROC曲線分析顯示，當miR-19a截斷值為0.69時，ROC曲線下面積為0.927(95%CI：0.888～0.966)，診斷急性腦梗死的靈敏度為93.9%、特異度為82.3%。結論急性腦梗死AR患者血小板miR-19a表達升高，是AR發(fā)生的獨立危險因素，可作為預測急性腦梗死發(fā)生AR的指標。

急性腦梗死；阿司匹林抵抗；微小RNA-19a

急性腦梗死是臨床常見的危急癥，具有較高的致死、致殘率，嚴重影響患者生存質量。研究[1]表明，血小板活化、黏附和聚集在血栓形成中發(fā)揮關鍵性作用，是腦梗死的重要病理基礎?？寡“逯委熓羌毙阅X梗死的常規(guī)治療方法之一，其中阿司匹林是常用的藥物[2]，然而患者會經常出現(xiàn)阿司匹林抵抗(AR)現(xiàn)象[3,4]。研究[5]表明，血小板活化涉及多種微小RNA(miRNA)表達變化，miRNA表達變化會影響血小板活性。微小RNA-19a(miR-19a)可通過影響內皮細胞黏附、增殖而影響血管新生，與血小板聚集關系密切[6]。本研究對49例急性腦梗死患者發(fā)生AR者的臨床資料作回顧性分析，并總結其危險因素。

1　資料與方法

1.1臨床資料2013年2月～2015年8月濰坊醫(yī)學院附屬益都中心醫(yī)院收治的急性腦梗死患者162例，男94例，女68例；年齡39～77(61.4±10.5)歲。均符合第四屆全國腦血管病會議修訂的診斷標準，并經影像學檢查確診，均為首次發(fā)病，發(fā)病時間4～72 h。排除標準：①具有出血傾向者；②血小板計數>450×109/L或<100×109/L；③合并有重要臟器功能障礙、腫瘤、造血系統(tǒng)疾病者；④近30 d行外科手術治療者，使用非甾體類抗炎藥、華法林、低分子肝素等可能影響血小板功能的藥物者；⑤對口服阿司匹林過敏者，或有其他禁忌證者。所有患者于入院當日開始口服阿司匹林腸溶片100 mg/d，服用阿司匹林10 d后，根據血小板聚集實驗結果將患者分為阿司匹林抵抗(AR)者(AR組，49例)和非AR者(非AR組，113例)。

2　結果

AR組血小板miR-19a表達量為0.78±0.09、2型糖尿病26例(53.1%)，非AR組血小板miR-19a表達量為0.59±0.11、2型糖尿病34例(30.1%)，兩組比較，P均<0.05。AR組男30例(61.2%)、女19例(38.8%)、高血壓32例(65.3%)、吸煙16例(32.7%)，對照組男64例(56.6%)、女49例(43.4%)、高血壓63例(55.8%)、吸煙31例(27.4%)，兩組比較，P均>0.05。兩組年齡、白細胞計數、紅細胞計數、血小板計數、纖維蛋白原、LDL-C、C反應蛋白、白蛋白、糖化血紅蛋白比較見表1，由表1可知，兩組各指標比較，P均>0.05。將血小板miR-19a表達量、2型糖尿病進行多因素Logistic回歸分析，顯示血小板miR-19a表達量升高是影響急性腦梗死患者發(fā)生AR的獨立危險因素(OR=4.82，95%CI：1.374～15.835)。ROC曲線分析顯示，當miR-19a截斷值為0.69時，ROC曲線下面積為0.927(95%CI：0.888～0.966)，診斷急性腦梗死的靈敏度為93.9%、特異度為82.3%。

表1　兩組年齡、白細胞計數、紅細胞計數、血小板計數、纖維蛋白原、LDL-C、C反應蛋白、白蛋白、糖化血紅蛋白比較±s)

3　討論

近年來，隨著人們生活方式的轉變及老齡化的加劇，急性腦梗死發(fā)病率呈逐年上升趨勢[7]，嚴重威脅人類生存健康。研究[8]證實，抑制血小板活化是有效預防腦梗死發(fā)生及復發(fā)的手段。阿司匹林是目前臨床上最為常用且療效確定的抗血小板藥物，可抑制血小板聚集[9]。然而文獻[10]報道，服用阿司匹林藥物者中有5.5%～65.0%發(fā)生AR。AR可增加急性腦梗死患者復發(fā)缺血性血管事件的風險，是缺血性血管事件復發(fā)的獨立危險因素[11]。本研究采用血小板聚集實驗判斷AR，結果顯示162例患者中發(fā)生AR者49例。

目前，AR發(fā)生機制尚未研究清楚，可能與服藥依從性、劑量及炎癥、疾病嚴重程度、血小板更新速度等有關[12]。本研究對AR與非AR患者一般臨床指標進行比較時，發(fā)現(xiàn)AR患者中2型糖尿病比例高于非AR患者，提示2型糖尿病可能是影響AR發(fā)生的危險因素。miRNA作為一種高度保守的單鏈非編碼RNA，研究[13]表明血小板活化過程中可出現(xiàn)多種miRNA表達變化。miR-19a作為miR-17-92基因簇編碼成員，參與調控血管內皮細胞黏附及增殖過程，與血管新生密切相關[14]。有研究[15]指出，miR-19a高表達可通過抑制凝血酶敏感蛋白1表達而抑制腫瘤組織血管新生。本研究顯示，AR者血小板miR-19a表達量顯著高于非AR者，說明急性腦梗死患者血小板miR-19a表達升高可能參與了AR發(fā)生。進一步對影響AR發(fā)生的因素進行分析，發(fā)現(xiàn)血小板miR-19a表達量是影響急性腦梗死患者發(fā)生AR的獨立危險因素；ROC曲線分析顯示，當miR-19a截斷值為0.69時，ROC曲線下面積為0.927(95%CI：0.888～0.966)，診斷急性腦梗死的靈敏度為93.9%、特異度為82.3%。說明急性腦梗死患者血小板miR-19a表達量可作為預測AR發(fā)生的生物學指標。

總之，急性腦梗死AR患者血小板miR-19a表達量升高，是AR發(fā)生的獨立危險因素，可作為預測急性腦梗死發(fā)生AR的指標。

[1] van Rooy MJ, Pretorius E. Metabolic syndrome, platelet activation and the development of transient ischemic attack or thromboembolic stroke[J]. Thromb Res, 2015,135(3):434-442.

[2] Ansara AJ, Nisly SA, Arif SA, et al. Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature[J]. Ann Pharmacother, 2010,44(5):851-862.

[4] Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review[J]. Br J Clin Pharmacol, 2008,66(2):222-232.

[5] 丁雪燕,宋曉偉,荊清,等.MicroRNA在血小板產生和激活中的作用[J].國際心血管病雜志,2013,40(3):161-163.

[6] 于宇,張淑蘭.miR-17-92基因簇研究進展[J].國際婦產科學雜志,2014,41(2):124-127.

[7] Fukuoka T, Hayashi T, Kato Y, et al. Clinical review of 24 patients with acute cholecystitis after acute cerebral infarction[J]. Intern Med, 2014,53(12):1321-1323.

[8] J?remo P, Eriksson M, Lindahl TL, et al. Platelets and acute cerebral infarction[J]. Platelets, 2013,24(5):407-411.

[9] Schrottmaier WC, Kral JB, Badrnya S, et al. Aspirin and P2Y12 Inhibitors in platelet-mediated activation of neutrophils and monocytes[J]. Thromb Haemost, 2015,114(3):478-489.

[10] Cai G, Zhou W, Lu Y, et al. Aspirin resistance and other aspirin-related concerns[J]. Neurol Sci, 2016,37(2):181-189.

[11] 林志堅,車秀娟,程欣,等.腦梗死患者阿司匹林抵抗與復發(fā)缺血性血管事件風險[J].卒中與神經疾病,2015,22(3):148-151.

[12] Floyd CN, Ferro A. Mechanisms of aspirin resistance[J]. Pharmacol Ther, 2014,141(1):69-78.

[13] Kaudewitz D, Skroblin P, Bender LH, et al. Association of microRNAs and YRNAs with platelet function[J]. Circ Res, 2016,118(3):420-432.

[14] Olive V, Jiang I, He L. mir-17-92, a cluster of miRNAs in the midst of the cancer network[J]. Int J Biochem Cell Biol, 2010,42(8):1348-1354.

Risk factors for aspirin resistance in patients with acute cerebral infarction

ZHANG Shijuan, SONG Yuning, LI Naikun, SUN Xipo, LI Bingxuan

(Yidu Center Hospital Affiliated to Weifang Medical University, Qingzhou 262500, China)

ObjectiveTo investigate the risk factors for aspirin resistance (AR) in patients with acute cerebral infarction. MethodsTotally 162 cases of patients with acute cerebral infarction received aspirin enteric-coated tablets 100 mg/d at the beginning of the day of admission. After taking aspirin 10 d, all patients were divided into the AR group (49 cases) and non-AR group (113 cases) according to the results of platelet aggregation test. The clinical data of patients were collected. The expression of microRNA-19a (miR-19a) in the platelets was detected by real-time fluorescence quantitative PCR. The influencing factors for the occurrence of AR were analyzed by Logistic regression analysis. The predictive value of expression of miR-19a in platelet for AR was analyzed by using receiver operating characteristic curve (ROC curve). ResultsThe expression level of miR-19a in the AR group was 0.78±0.09, the type 2 diabetes were found in 26 cases (53.1%), while in the non-AR group, the expression level of miR-19a was 0.59±0.11, the type 2 diabetes were found in 34 cases (30.1%), and significant difference was found between the two groups, all P<0.05. Multivariate Logistic regression analysis showed that the increased expression of miR-19a in platelet was an independent risk factor for AR in patients with acute cerebral infarction (OR=4.82, 95% CI:1.374-15.835). ROC curve analysis showed that, when miR-19a cutoff value was 0.69, the area under the ROC curve was 0.927 (95% CI:0.888-0.966), the sensitivity was 93.9% and the specificity was 82.3%. ConclusionThe expression of miR-19a in platelet of AR in patients with acute cerebral infarction is increased, which is an independent risk factor for the occurrence of AR and may be used as an indicator to predict the occurrence of AR in acute cerebral infarction.

acute cerebral infarction; aspirin resistance; micro RNA-19a

濰坊市科技局科研課題資助項目(2015ws109)。

10.3969/j.issn.1002-266X.2016.15.022

R741.02

B

1002-266X(2016)15-0062-03

2016-02-17)